Lin C, Verma V, Lazenby A, et al. - Whether chemoimmunotherapy (CIT) with oregovomab [anti–cancer antigen (CA)-125], followed by stereotactic body radiotherapy (SBRT) with the radiosensitizer nelfinavir, serves as a safe and effective means to treat pancreatic cancer was investigated in this phase I/II trial. Researchers also focused on the immunologic correlates of this treatment regimen. Eleven patients were enrolled, among those, high CA-125 was found in 10; 9 patients received oregovomab because 1 patient experienced unexpected cardiac-related death. SBRT was used to treat 10 patients and 4 underwent resection. Any grade ≥ 3 event was experienced by 6/11 patients. The estimated median survival was 13 months and time to progression was 8.6 months. Overall, findings revealed the feasibility as well as the safety of a combined pancreatic cancer multimodality approach utilizing CIT and radiosensitized radiotherapy in this patient population. T-cell immunity can result from the delivery of immunotherapy. Experts advised re-assessment with modern systemic paradigms.